Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment

Journal of Immunology

Volumn 192, Issue 5, 2014, Pages 2505-2513

  Wilmott, James S ^a,b   Haydu, Lauren E ^a,b,d   Menzies, Alexander M ^a,b   Lum, Trina ^c   Hyman, Jessica ^a,e   Thompson, John F ^a,b,c   Hersey, Peter ^a,b   Kefford, Richard F ^a,b,f   Scolyer, Richard A ^a,b,c   Long, Georgina V ^a,b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD8 ANTIGEN; DABRAFENIB; GAMMA INTERFERON; INTERLEUKIN 8; KI 67 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VEMURAFENIB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84896529503     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302616     Document Type: Article

References (55)

1. Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
2. Long, G. V., A. M. Menzies, A. M. Nagrial, L. E. Haydu, A. L. Hamilton, G. J. Mann, T. M. Hughes, J. F. Thompson, R. A. Scolyer, and R. F. Kefford. 2011. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29: 1239-1246.
3. Tsai, J., J. T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N. K. Haass, et al. 2008. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105: 3041-3046.
4. Sondergaard, J. N., R. Nazarian, Q. Wang, D. Guo, T. Hsueh, S. Mok, H. Sazegar, L. E. MacConaill, J. G. Barretina, S. M. Kehoe, et al. 2010. Differential sensitivity of melanoma cell lines with BRAF(V600E) mutation to the specific Raf inhibitor PLX4032. J. Transl. Med. 8: 39.
5. Sumimoto, H., F. Imabayashi, T. Iwata, and Y. Kawakami. 2006. The BRAFMAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203: 1651-1656.
6. Sumimoto, H., M. Miyagishi, H. Miyoshi, S. Yamagata, A. Shimizu, K. Taira, and Y. Kawakami. 2004. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031-6039.
7. Long, G. V., J. S. Wilmott, L. E. Haydu, V. Tembe, R. Sharma, H. Rizos, J. F. Thompson, J. Howle, R. A. Scolyer, and R. F. Kefford. 2013. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 26: 499-508.
8. Trunzer, K., A. C. Pavlick, L. Schuchter, R. Gonzalez, G. A. McArthur, T. E. Hutson, S. J. Moschos, K. T. Flaherty, K. B. Kim, J. S. Weber, et al. 2013. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31: 1767-1774.
9. Wilmott, J. S., G. V. Long, J. R. Howle, L. E. Haydu, R. N. Sharma, J. F. Thompson, R. F. Kefford, P. Hersey, and R. A. Scolyer. 2012. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18: 1386-1394.
10. Frederick, D. T., A. Piris, A. P. Cogdill, Z. A. Cooper, C. Lezcano, C. R. Ferrone, D. Mitra, A. Boni, L. P. Newton, C. Liu, et al. 2013. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19: 1225-1231.
11. Khalili, J. S., S. Liu, T. G. Rodríguez-Cruz, M. Whittington, S. Wardell, C. Liu, M. Zhang, Z. A. Cooper, D. T. Frederick, Y. Li, et al. 2012. Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18: 5329-5340.
12. Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, et al; BRIM-3 Study Group. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364: 2507-2516.
13. Flaherty, K. T., I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. J. O'Dwyer, R. J. Lee, J. F. Grippo, K. Nolop, and P. B. Chapman. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363: 809-819.
14. Wajapeyee, N., R. W. Serra, X. Zhu, M. Mahalingam, and M. R. Green. 2008. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374.
15. Hauschild, A., J. J. Grob, L. V. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. U. Blank, W. H. Miller, Jr., E. Kaempgen, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365.
16. Flaherty, K. T., J. R. Infante, A. Daud, R. Gonzalez, R. F. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, et al. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367: 1694-1703.
17. Johannessen, C. M., J. S. Boehm, S. Y. Kim, S. R. Thomas, L. Wardwell, L. A. Johnson, C. M. Emery, N. Stransky, A. P. Cogdill, J. Barretina, et al. 2010. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
18. Montagut, C., S. V. Sharma, T. Shioda, U. McDermott, M. Ulman, L. E. Ulkus, D. Dias-Santagata, H. Stubbs, D. Y. Lee, A. Singh, et al. 2008. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68: 4853-4861.
19. Nazarian, R., H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M.-K. Lee, N. Attar, H. Sazegar, et al. 2010. Melanomas acquire resistance to BRAF( V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
20. Poulikakos, P. I., C. Zhang, G. Bollag, K. M. Shokat, and N. Rosen. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
21. Smalley, K. S. M., N. K. Haass, P. A. Brafford, M. Lioni, K. T. Flaherty, and M. Herlyn. 2006. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5: 1136-1144.
22. Villanueva, J., A. Vultur, J. T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, A. K. Cipolla, B. Wubbenhorst, X. Xu, P. A. Gimotty, D. Kee, et al. 2010. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
23. Straussman, R., T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, et al. 2012. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504.
24. Richmond, A., J. Yang, and Y. Su. 2009. The good and the bad of chemokines/ chemokine receptors in melanoma. Pigment Cell Melanoma Res. 22: 175-186.
25. Schadendorf, D., A. Möller, B. Algermissen, M. Worm, M. Sticherling, and B. M. Czarnetzki. 1993. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151: 2667-2675.
26. Ugurel, S., G. Rappl, W. Tilgen, and U. Reinhold. 2001. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19: 577-583.
27. Waugh, D. J. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735-6741.
28. Falchook, G. S., G. V. Long, R. Kurzrock, K. B. Kim, T. H. Arkenau, M. P. Brown, O. Hamid, J. R. Infante, M. Millward, A. C. Pavlick, et al. 2012. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893-1901.
29. Sosman, J. A., K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, G. A. McArthur, T. E. Hutson, S. J. Moschos, K. T. Flaherty, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366: 707-714.
30. Long, G. V., U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto, P. B. Chapman, I. Puzanov, A. Hauschild, C. Robert, A. Algazi, et al. 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13: 1087-1095.
31. Larkin, J. M. G., P. Queirolo, A. M. Arance, M. P. Brown, A. Hauschild, M. Del Vecchio, G. A. McArthur, B. Neyns, J. C. Becker, J. Hansson, et al. 2012. An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. J. Clin. Oncol. 30(Suppl): Abstract 8517.
32. Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45: 228-247.
33. Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A. T. Van Oosterom, M. C. Christian, and S. G. Gwyther. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216.
34. Potter, D. M., L. H. Butterfield, S. J. Divito, C. A. Sander, and J. M. Kirkwood. 2012. Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J. Immunol. Methods 376: 108-112.
35. Ueno, T., M. Toi, H. Saji, M. Muta, H. Bando, K. Kuroi, M. Koike, H. Inadera, and K. Matsushima. 2000. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6: 3282-3289.
36. Sanford, D. E., B. A. Belt, R. Z. Panni, A. Mayer, A. D. Deshpande, D. Carpenter, J. B. Mitchem, S. M. Plambeck-Suess, L. A. Worley, B. D. Goetz, A. Wang-Gillam, et al. 2013. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 19: 3404-3415.
37. Knight, D. A., S. F. Ngiow, M. Li, T. Parmenter, S. Mok, A. Cass, N. M. Haynes, K. Kinross, H. Yagita, R. C. Koya, et al. 2013. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123: 1371-1381.
38. Díaz-Valdés, N., M. Basagoiti, J. Dotor, F. Aranda, I. Monreal, J. I. Riezu-Boj, F. Borrás-Cuesta, P. Sarobe, and E. Feijoó. 2011. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 71: 812-821.
39. Bailey, C., R. Negus, A. Morris, P. Ziprin, R. Goldin, P. Allavena, D. Peck, and A. Darzi. 2007. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin. Exp. Metastasis 24: 121-130.
40. Dwyer, R. M., S. M. Potter-Beirne, K. A. Harrington, A. J. Lowery, E. Hennessy, J. M. Murphy, F. P. Barry, T. O'Brien, and M. J. Kerin. 2007. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res. 13: 5020-5027.
41. Qian, B.-Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, and J. W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
42. Wilmott, J. S., R. A. Scolyer, G. V. Long, and P. Hersey. 2012. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology 1: 997-999.
43. Lanca, T., M. F. Costa, N. Goncalves-Sousa, M. Rei, A. R. Grosso, C. Penido, and B. Silva-Santos. 2013. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gd T lymphocytes to tumor beds. J. Immunol. 190: 6673-6680.
44. Monti, P., B. E. Leone, F. Marchesi, G. Balzano, A. Zerbi, F. Scaltrini, C. Pasquali, G. Calori, F. Pessi, C. Sperti, et al. 2003. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 63: 7451-7461.
45. Li, M., D. A. Knight, L. A Snyder, M. J. Smyth, and T. J. Stewart. 2013. A role for CCL2 in both tumor progression and immunosurveillance. OncoImmunology 2: e25474.
46. Hong, D. S., L. Vence, G. Falchook, L. G. Radvanyi, C. Liu, V. Goodman, J. J. Legos, S. Blackman, A. Scarmadio, R. Kurzrock, et al. 2012. BRAF (V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin. Cancer Res. 18: 2326-2335.
47. Dorner, B. G., A. Scheffold, M. S. Rolph, M. B. Hüser, S. H. E. Kaufmann, A. Radbruch, I. E. A. Flesch, and R. A. Kroczek. 2002. MIP-1a, MIP-1b, RANTES, and ATAC/lymphotactin function together with IFN-g as type 1 cytokines. Proc. Natl. Acad. Sci. USA 99: 6181-6186.
48. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
49. Boni, A., A. P. Cogdill, P. Dang, D. Udayakumar, C.-N. J. Njauw, C. M. Sloss, C. R. Ferrone, K. T. Flaherty, D. P. Lawrence, D. E. Fisher, et al. 2010. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70: 5213-5219.
50. Landsberg, J., J. Kohlmeyer, M. Renn, T. Bald, M. Rogava, M. Cron, M. Fatho, V. Lennerz, T. Wölfel, M. Hölzel, and T. Tüting. 2012. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490: 412-416.
51. Schilling, B., A. Sucker, K. Griewank, F. Zhao, B. Weide, A. Görgens, B. Giebel, D. Schadendorf, and A. Paschen. 2013. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int. J. Cancer 133: 1653-1663.
52. Finke, J., J. Ko, B. Rini, P. Rayman, J. Ireland, and P. Cohen. 2011. MDSC as a mechanism of tumor escape from sunitinib mediated anti-Angiogenic therapy. Int. Immunopharmacol. 11: 856-861.
53. Lindau, D., P. Gielen, M. Kroesen, P. Wesseling, and G. J. Adema. 2013. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138: 105-115.
54. Amaravadi, R., K. Kim, K. Flaherty, P. Chapman, I. Puzanov, J. Sosman, A. Ribas, R. Lee, K. Nolop, and G. McArthur. 2011. Prolonged responses to vemurafenib in patients with BRAF V600E mutant melanoma with low tumor burden at baseline. Pigment Cell Res. 24: 1024.
55. Ascierto, P. A., J. M. Kirkwood, J.-J. Grob, E. Simeone, A. M. Grimaldi, M. Maio, G. Palmieri, A. Testori, F. M. Marincola, and N. Mozzillo. 2012. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10: 85.